SEC filings confirm that DRW Securities, LLC, identified as a ten percent owner of Aditxt, Inc. (NASDAQ: ADTX), reported a transaction involving the sale of common stock totaling $1,001 on June 17, 2026. The disposal encompassed 126,772 shares of Aditxt common stock, executed at a price of $0.0079 per share. Following the completion of this transaction, DRW Securities, LLC holds zero shares of Aditxt, Inc. common stock directly.
This insider divestiture coincides with a sharp depreciation in Aditxt's share price. Over the preceding week, the stock declined by 66%, trading at $0.01 at the time of the report. Market data indicates that Aditxt possesses a market capitalization of merely $0.01 million. Financial health assessments classify the company's status as "WEAK." Investors seeking further analytical metrics may access additional data points provided by InvestingPro.
Concurrent with the insider transaction, Aditxt disclosed significant corporate developments. The company announced that its subsidiary, Ignite Proteomics LLC, will transition to public status through a special purpose acquisition company (SPAC) transaction. This deal values Ignite at approximately $150 million and will establish it as an independent publicly traded entity. To facilitate this transition, Aditxt appointed Jeffrey M. Busch as interim CEO, allowing him to continue leading Ignite Proteomics.
Further structural adjustments include a 1-for-27 reverse stock split approved by stockholders and effective on May 18, 2026. The company also disclosed a $1.25 million private placement of senior unsecured promissory notes, carrying a 10% annual interest rate and maturing on September 30, 2026. Additionally, Aditxt confirmed regained compliance with Nasdaq listing standards via a letter from The Nasdaq Stock Market LLC. This compliance was achieved through an increase in stockholders' equity, as outlined in the company's recent Annual Report.
These events highlight ongoing strategic and financial maneuvers by Aditxt. The liquidation of DRW Securities' position, combined with the subsidiary IPO and financial restructuring, underscores the complex operational environment within the biotech and financial sectors.